It been a while since Anteris advised the market on internal NPV calculations. With the advances made since then there must be a reasonable reduction in risk metrics. It will be very interesting to hear there next valuation.
Ann: 30-day Haemodynamic Results from the DurAVR US EFS Trial, page-2
-
- There are more pages in this discussion • 73 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$18.80 |
Change
0.250(1.35%) |
Mkt cap ! $365.4M | |||
| Open | High | Low | Value | Volume |
| $18.80 | $19.15 | $18.70 | $36.45K | 1.927K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 38 | $18.51 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $18.92 | 345 | 1 |
View Market Depth
| Last trade - 11.51am 28/06/2024 (20 minute delay) ? |
| AVR (ASX) Chart |